head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing Ltd.
ISSN: 1312-773X (Online)
Issue: 2020, vol. 26, issue2
Subject Area: Medicine
-
DOI: 10.5272/jimab.2020262.3208
Published online: 25 June 2020

Original article

J of IMAB. 2020 Apr-Jun;26(2):3208-3212
ANTIMICROBIAL RESISTANCE OF BULGARIAN ISOLATES MORAXELLA CATARRHALIS DURING THE PERIOD 1999-2018
Raina GergovaORCID logo Corresponding Autoremail, Rumyana MarkovskaORCID logo,
Department of Medical Microbiology, Faculty of Medicine, Medical University - Sofia, Bulgaria.

ABSTRACT:
The purpose of this study was to assess the levels of antimicrobial susceptibility during a period of the last 20 years among Moraxella catarrhalis isolates and to evaluate their resistance mechanisms.
Material/Methods: A total of 618 Bulgarian clinical significant isolates M.catarrhalis was collected during the period 1999–2018 from patients to assess the current levels of antimicrobial susceptibility and to evaluate the beta-lactam resistance mechanisms. The minimum inhibitory concentrations (MICs) by E-test were determined against: penicillin, ampicillin, amoxicillin+clavulanic acid, cefalexin, cefuroxime, cefixime, cefotaxime, levofloxacin, azithromycin, clarithromycin, tetracycline, sulfamethoxazole + trimethoprim. PCR examination of genes encoding beta-lactamases was done.
Results: Almost all (98.88%) of the tested strains M. catarrhalis showed positive cefinase test and were demonstrated elevated MICs and a lack of susceptibility to penicillin, ampicillin and cefalexin. An increase of resistance to cephalosporin of second and third generations (cefixime) was found. Higher MIC values of cefuroxime and cefixime than these of cefotaxime were detected. PCRs revealed that bro-1 genes (94.11%) were more frequent than bro-2.
Conclusions: The results of examined 20 years period showed that nearly all Bulgarian isolates of M. catarrhalis in the last years become resistant to penicillins and first generation cephalosporins via beta-lactamases, encoded predominantly by bro-1 gene. An increase of the resistance to members of second and third generation (cefixime) cephalosporin’s and slower to other antimicrobials was found. The rapid development of resistance in recent years to the most popular antimicrobial agents affects the recommendations regarding the initial approach to therapy.

Keywords: Moraxella catarrhalis, beta-lactamases, bro-1, bro-2, PCR,,

pdf - Download FULL TEXT /PDF 750 KB/
Please cite this article as: Gergova R, Markovska R. Antimicrobial resistance of Bulgarian isolates Moraxella catarrhalis during the period 1999-2018. J of IMAB. 2020 Apr-Jun;26(2):3208-3212. DOI: 10.5272/jimab.2020262.3208

Corresponding AutorCorrespondence to: Assoc. Prof. Raina Gergova, MD, PhD, Department of Medical Microbiology, Faculty of Medicine, Medical University of Sofia; 2, Zdrave str. 1431 Sofia, Bulgaria; E-mail: rtgergova@gmail.com

REFERENCES:
1. Gergova RT, Petrova G, Gergov S, Minchev P, Mitov I, Strateva T. Microbiological features of upper respiratory tract infections in bulgarian children for the period 1998-2014. Balkan Med J. 2016; 33(6):675-80. [Crossref]
2. Murphy TF. Moraxella catarrhalis, Kingella, and other Gram-Negative Cocci. In: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Authors: Bennett JE, Dolin R, Blaser MJ. 9th Edition. Elsevier. September 12, 2019. Chapter 213. pp.2628-2635e3. [Internet]
3. Pichichero ME. Ten-Year Study of Acute Otitis Media in Rochester, NY. Pediatr Infect Dis J 2016; 35:1027.
4. Georgieva B, Gergova R, Perenovska P, Miteva D, Parina S, Korsun N, et al. Infectious Pathogens that Could Trigger Cough in Children Outside Winter Epidemic Season. Ann Microbiol Infect Dis. 2019, 2(1), PP 52-57.
5. Gergova R, Markovska R, Mitov I. Antimicrobial resistance and production of beta-lactamases in Bulgarian clinical isolates Moraxella catarrhalis. Ann Microbiol. 2009 Mar; 59:169-172. [Crossref]
6. Micoli F, Costantino P, Adamo R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol Rev. 2018 May 1;42(3):388-423. [PubMed] [Crossref]
7. Perez AC, Murphy TF. A Moraxella Catarrhalis Vaccine to Protect Against Otitis Media and Exacerbations of COPD: An Update on Current Progress and Challenges. Hum Vaccin Immunother. 2017 Oct 3;13(10):2322-2331. [PubMed]  [Crossref]
8. Yamada K, Arai K, Saito R. Antimicrobial susceptibility to в-lactam antibiotics and production of BRO в-lactamase in clinical isolates of Moraxella catarrhalis from a Japanese hospital. J Microbiol Immunol Infect 2017; 50:386.
9. Lafontaine ER, Wall D, Vanlerberg SL, Donabedian H, Sledjeski DD. Moraxella Catarrhalis Coaggregates With Streptococcus Pyogenes and Modulates Interactions of S. Pyogenes With Human Epithelial Cells. Infect Immun. 2004 Nov;72(11):6689-93. [PubMed] [Crossref].
10. Perez AC, Pang B, King LB, Tan L, Murrah KA, Reimche JL, et al. Residence of Streptococcus Pneumoniae and Moraxella Catarrhalis Within Polymicrobial Biofilm Promotes Antibiotic Resistance and Bacterial Persistence in Vivo. Pathog Dis. 2014 Apr;70(3):280-8. [PubMed] [Crossref]
11. Tan A, Li W-S, Verderosa AD, Blakeway LV, Mubaiwa TD, Totsika M, et al. Moraxella Catarrhalis NucM Is an Entry Nuclease Involved in Extracellular DNA and RNA Degradation, Cell Competence and Biofilm Scaffolding. Sci Rep. 2019 Feb 22;9(1):2579. [PubMed] [Crossref]
12. Gergova R. Microbiological, Immunological and Molecular Genetic Studies on Moraxella catarrhalis isolates, from patients with respiratory infections [dissertation], [Sofia], Medical University of Sofia, 2008, 211p.
13. European Committee on Antimicrobial Susceptibility Testing. Clinical Breakpoint Tables – bacteria; Version 9.0, 2019.
14. Verhaegh SJC, Streefland A, Dewnarain JK, Farrell DJ, Van Belkum Alex, Hays JP. Age-related genotypic and phenotypic differences in Moraxella catarrhalis isolates from children and adults presenting with respiratory disease in 2001–2002. Microbiol. 2008;154:1178–1184. [PubMed]
15. Khan MA, Northwood JB, Levy F, Verhaegh SJ, Farrell DJ, Van Belkum A, et al. Bro{beta}-lactamase and antibiotic resistances in a global cross-sectional study of Moraxella catarrhalis from children and adults. J Antimicrob Chemother. 2010;65:91–97. [PubMed]
16. Saito R, Nonaka S, Fujinami Y, Matsuoka S, Nakajima S, Nishiyama H, et al. The frequency of BRO b-lactamase and its relationship to antimicrobial susceptibility and serum resistance in Moraxella catarrhalis. J Infect Chemother. 2014; 20:6e8 [PubMed]
17. Yanagihara K, Kadota J, Aoki N, Matsumoto T, Yoshida M, Yagisawa M, et al. Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: general view of the pathogens’ antibacterial susceptibility. J Infect Chemother. 2015;21:410e20. [PubMed]
18. Shaikh SB, Ahmed Z, Arsalan SA,  Shafiq S. Prevalence and resistance pattern of Moraxella catarrhalis in community-acquired lower respiratory tract infections. Infect Drug Resist. 2015;8:263–267. [PubMed]
19. Krol-Turminska K, Olender A. Alternations in DNA Gyrase Genes in Low-Level Fluoroquinolone-Resistant Moraxella catarrhalis Strains Isolated in Poland. Infect Drug Resist. 2018 Aug 6;11:1047-1053. [PubMed] [Crossref]
20. Spaniol V, Bernhard S, Aebi C. Moraxella Catarrhalis AcrAB-OprM Efflux Pump Contributes to Antimicrobial Resistance and Is Enhanced During Cold Shock Response. Antimicrob Agents Chemother. 2015 Apr;59(4):1886-94. [PubMed] [Crossref]
21. Kasai A, Ohta A, Maeda Y, Yamada K, Tao K, Saito R. Novel mechanism responsible for high-level macrolide resistance in Moraxella catarrhalis. Infect Drug Resist. 2018 November, 11, 2137-2140. [PubMed].

Received: 25 July 2019
Published online: 25 June 2020

back to Online Journal